Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT

J Schwenck, H Rempp, G Reischl, S Kruck… - European journal of …, 2017 - Springer
Purpose Prostate-specific membrane antigen (PSMA) is expressed ubiquitously on the
membrane of most prostate tumors and its metastasis. While PET/CT using 11 C-choline …

A practical guide for perioperative smoking cessation

H Iida, T Kai, M Kuri, K Tanabe, M Nakagawa… - Journal of …, 2022 - Springer
The perioperative management of patients who are smokers presents anesthesiologists with
various challenges related to respiratory, circulatory, and other clinical problems. Regarding …

[HTML][HTML] Surgical management of oligometastatic non-small cell lung cancer

NM Novoa, G Varela, MF Jiménez - Journal of thoracic disease, 2016 - ncbi.nlm.nih.gov
The oligometastatic stage IV non-small cell lung cancer (NSCLC) offers a new surgical
opportunity. New reported data is showing that surgery can offer a reasonable benefit, in …

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II …

F Verghote, L Poppe, S Verbeke, P Dirix, M Albersen… - BMC cancer, 2021 - Springer
Background The outcome of patients with muscle-invasive bladder cancer (MIBC) remains
poor, despite aggressive treatments. Inadequate primary staging, classically performed by …

Prognostic value of combining a quantitative image feature from positron emission tomography with clinical factors in oligometastatic non-small cell lung cancer

GL Jensen, CM Yost, DS Mackin, DV Fried… - Radiotherapy and …, 2018 - Elsevier
Background and purpose Oligometastatic non-small cell lung cancer (NSCLC) is a
heterogeneous condition with few known risk stratification factors. A quantitative imaging …

Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression

Z Sun, S Zhou, J Tang, T Ye, J Li, D Liu, J Zhou… - …, 2018 - thelancet.com
Background Cancer treatment is based on tumor staging. Curative intent is only applied to
localized tumors. Recent studies show that oligometastatic patients who have limited …

[HTML][HTML] Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases

Z Wang, SG Gao, Q Xue, XT Guo, LX Wang… - Journal of Thoracic …, 2018 - ncbi.nlm.nih.gov
Background Previous studies have demonstrated that survival of patients with non-small cell
lung cancer (NSCLC) with oligometastasis may benefit from local treatment. The purpose of …

[HTML][HTML] Oligo-Recurrence in Lung Cancer; The Most Curable State Among Advanced Disease?

Y Shimada - Cancers, 2024 - mdpi.com
Despite the introduction of effective systemic therapies and advancements in precision
medicine, recurrence or progression remains common in advanced non-small cell lung …

Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

YH Chen, UC Ho, LT Kuo - Cancers, 2022 - mdpi.com
Simple Summary Approximately 7–50% of patients with non-small-cell lung cancer (NSCLC)
develop oligometastases, which are new tumors found in another part of the body, arising …

[HTML][HTML] Surgical approach in oligometastatic non-small cell lung cancer

D Patrini, N Panagiotopoulos, B Bedetti… - Annals of …, 2018 - ncbi.nlm.nih.gov
The vast majority of lung cancer (80%) are non-small cell lung cancer (NSCLC) presenting
in huge proportion of patients in a metastatic stage at the time of diagnosis with an overall …